{"id":164253,"date":"2026-11-22T03:43:12","date_gmt":"2026-11-22T03:43:12","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/164253\/"},"modified":"2026-11-22T03:43:12","modified_gmt":"2026-11-22T03:43:12","slug":"roches-next-major-breast-cancer-drug-wilserdly-wins-fda-nod","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/164253\/","title":{"rendered":"Roche\u2019s next major breast cancer drug, Wilserdly, wins FDA nod"},"content":{"rendered":"<p>No breast cancer asset in Roche\u2019s pipeline carries a higher valuation than giredestrant. In fact, the Swiss drugmaker\u2019s pharmaceuticals chief has touted the oral SERD as potentially the company\u2019s \u201clargest-selling product.\u201d<\/p>\n<p>On Monday, giredestrant took the first step toward what some analysts project could exceed $10 billion in peak annual sales, <a href=\"https:\/\/www.fda.gov\/drugs\/cancer-approvals\/fda-approves-giredestrant-combination-everolimus-er-positive-her2-negative-esr1-mutated-locally\" rel=\"nofollow noopener\" target=\"_blank\">winning FDA approval<\/a> in combination with everolimus for certain patients with HR-positive, HER2-negative breast cancer.<\/p>\n<p>However, despite a nearer target action date at the end of November, the FDA approval wasn\u2019t about the more important early-stage breast cancer setting. Instead, the agency cleared giredestrant, to be marketed as Wilserdly, for patients with previously treated ESR1-mutated advanced tumors, the same narrow indication where two other oral selective estrogen receptor degraders (SERDs) are already approved. The FDA\u2019s decision in this niche came a month ahead of schedule.<\/p>\n<p>Nevertheless, in its Nov. 16 announcement, Roche was <a href=\"https:\/\/www.roche.com\/media\/releases\/med-cor-2026-11-16b\" rel=\"nofollow noopener\" target=\"_blank\">quick to highlight<\/a> that Wilserdly-everolimus is so far the only oral SERD combo to significantly outperform standard endocrine therapy in a phase 3 trial where all patients had previously tried a CDK4\/6 inhibitor, which has become the standard of care in first-line treatment.<\/p>\n<p>In the phase 3 evERA trial, Wilserdly-everolimus reduced the risk of progression or death by 62% compared with standard endocrine therapy plus everolimus among patients with CDK4\/6-pretreated, ESR1-mutated, HR-positive, HER2-negative breast cancer. Median progression-free survival reached 10 months for the Wilserdly arm versus 5.5 months for the comparator group.<\/p>\n<p>Before Wilserdly\u2019s arrival, the FDA had approved <a href=\"https:\/\/www.fiercepharma.com\/pharma\/menarini-shows-big-pharmas-how-first-approval-oral-serd-breast-cancer\" rel=\"nofollow noopener\" target=\"_blank\">Menarini\u2019s Orserdu<\/a> and <a href=\"https:\/\/www.fiercepharma.com\/pharma\/eli-lilly-oral-serd-inluriyo-passes-muster-fda-breast-cancer\" rel=\"nofollow noopener\" target=\"_blank\">Eli Lilly\u2019s Inluriyo<\/a>, also in second-line ESR1-mutated tumors, a resistance mechanism that often develops in HR+\/HER2- metastatic breast cancer after aromatase inhibitor therapy.\u00a0<\/p>\n<p>In September, Lilly escalated the oral SERDs\u2019 ESR1 competition through an FDA label expansion for use alongside the company\u2019s CDK4\/6 inhibitor Verzenio. In the phase 3 Ember-3 trial, Inluriyo-Verzenio <a href=\"https:\/\/www.fiercepharma.com\/pharma\/eli-lilly-escalates-oral-serd-battle-fda-approval-inluriyo-verzenio-combo\" rel=\"nofollow noopener\" target=\"_blank\">led to<\/a> a 47% PFS benefit versus Inluriyo alone, extending median PFS to 11.1 months, versus 5.5 months, respectively.\u00a0<\/p>\n<p>Amid the second-line battle, the FDA <a href=\"https:\/\/www.fiercepharma.com\/pharma\/fda-approves-astrazeneca-etcamah-opening-ctdna-guided-treatment-shift-breast-cancer\" rel=\"nofollow noopener\" target=\"_blank\">surprised<\/a> industry watchers with an approval for AstraZeneca\u2019s Etcamah in a novel first-line-switch setting for patients who developed ESR1 mutation during initial first-line treatment with an aromatase inhibitor and a CDK4\/6 drug. The go-ahead was controversial because it went against a negative advisory committee recommendation, and because the phase 3 Serena-6 trial didn\u2019t answer whether that first-line-switch approach works at least as well as the traditional method of treating patients upon disease progression.<\/p>\n<p>Meanwhile, both <a href=\"https:\/\/www.fiercepharma.com\/pharma\/astrazeneca-etcamah-flunks-first-line-breast-cancer-trial-adding-oral-serds-failure-record\" rel=\"nofollow noopener\" target=\"_blank\">Etcamah<\/a> and <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/roche-details-oral-serd-giredestrant-first-line-flop-breast-cancer-head-held-high\" rel=\"nofollow noopener\" target=\"_blank\">Wilserdly<\/a> failed in the first-line setting, where ESR1 mutations are rare.\u00a0<\/p>\n<p>Despite the first-line flop, Roche Pharmaceuticals CEO Teresa Graham still <a href=\"https:\/\/www.fiercepharma.com\/pharma\/roche-pharma-ceo-maintains-oral-serd-could-be-largest-product-company-history-despite-data\" rel=\"nofollow noopener\" target=\"_blank\">argued<\/a> that Wilserdly \u201ccould be our largest-selling product.\u201d The Swiss pharma has placed its biggest bet on adjuvant treatment of early-stage breast cancer, which, as Graham noted, sees three times more drug-treated patients than in the first-line metastatic setting, plus a much longer treatment duration.\u00a0<\/p>\n<p>\u201cIt is really important to remember that the first-line metastatic breast cancer setting only represented around 10% of the overall giredestrant opportunity,\u201d whereas the adjuvant use accounts for &#8220;about 70%,&#8221; she said during an investor call in April.<\/p>\n<p>In the adjuvant setting, Roche\u2019s lidERA trial has succeeded, showing a statistically significant invasive disease-free survival benefit for Wilserdly versus standard endocrine therapy. The FDA is scheduled to rule on that potential first-in-class adjuvant use by Nov. 30. And Roche<a href=\"https:\/\/www.fiercepharma.com\/pharma\/vabysmo-shows-signs-reacceleration-roche-gears-busy-2027\" rel=\"nofollow noopener\" target=\"_blank\"> expects<\/a> a single-arm sub-study to answer some critical CDK4\/6 combination questions this year.\u00a0<\/p>\n<p>The company has put Wilserdly\u2019s peak sales projection at above 3 billion Swiss francs. In an October note, Jefferies\u2019 analysts modeled risk-adjusted Wilserdly revenues of 4.8 billion Swiss francs by 2034, versus a consensus of 6.6 billion Swiss francs.<\/p>\n","protected":false},"excerpt":{"rendered":"No breast cancer asset in Roche\u2019s pipeline carries a higher valuation than giredestrant. In fact, the Swiss drugmaker\u2019s&hellip;\n","protected":false},"author":2,"featured_media":164254,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[207,2994,2991,41939,146,2536,134,75132],"class_list":["post-164253","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-breast-cancer","tag-drug-approval","tag-fda-approval","tag-fierce-pharma-homepage","tag-marketing","tag-pharma","tag-roche","tag-wilserdly"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117658033083986950","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/164253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=164253"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/164253\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/164254"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=164253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=164253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=164253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}